Nantworks Acquires Sorrento Therapeutics Inc (NASDAQ:SRNE) Subsidiary For $90 Million

NantWorks has acquired Igdrasol, a wholly-owned subsidiary of Sorrento Therapeutics Inc (NASDAQ:SRNE) for $90 million. The deal is part of the company’s plans for achieving a breakthrough in the cancer treatment domain. Igdrasol is underway a Phase 3 trial for cancer treatment through the Cynviloq drug. As an alternative to the cancer treatment drug Abraxane […]

Technical Update: Sorrento Therapeutics Inc. (NASDAQ:SRNE), Kingold Jewelry Inc. (NASDAQ:KGJI), Voxeljet AG (ADR) (NYSE:VJET)

Boston, MA 04/09/2014 (wallstreetpr) – Sorrento Therapeutics Inc. (NASDAQ:SRNE) is currently trading below its 50 day and 200 day moving average at $11.87 and $9.21 which is a bearish sign when it comes to short term traders. Short term traders can go short on this stock with a stop loss level at $9.10 with a target […]

Did You Know This? Sorrento Therapeutics Inc (NASDAQ:SRNE), Zuoan Fashion Ltd (ADR) (NYSE:ZA), Open Text Corporation (USA) (NASDAQ:OTEX)

Boston, MA 03/21/2014 (wallstreetpr) – Sorrento Therapeutics Inc (NASDAQ:SRNE) continues to strike the right cord with investors. Shares of the company have maintained their uptrend without showing any signs of fatigue. The uptrend gained energy following the announcement that industry veteran Mark Durand was joining the company’s board of directors. The management described Durand as […]